Pharmaceutical Business review

Sorin Group and Greatbatch sign collaborative agreement

Magnetic resonance imaging (MRI) conditional approved devices are critical to allow patients with active implantable medical devices to safely have an MRI for diagnostic evaluation.

Catherine Picard, vice-president of R&D at Sorin Group, said: “We are very excited by the opportunity to leverage Greatbatch’s eM-able technology to accelerate our MRI program and deliver MRI conditional systems to patients and physicians worldwide in the shortest possible time.”